A RANGE OF RESOURCES TO HELP SUCCESSFULLY INTEGRATE EVERY-2-MONTH VOCABRIA + REKAMBYS INTO YOUR CLINIC
Treatment Planner
The Treatment Planner has been designed to make scheduling appointments for every-2-month VOCABRIA + REKAMBYS easier for you and your team.
Get started
Preparation and injection tools
A summary of preparation and injection steps that can be viewed online.
PM-GB-CBR-WCNT-230005 | July 2024
To support you in planning and implementation in your clinic.
PM-GB-CBR-WCNT-230007 | July 2024
Administration Video
As the correct preparation and administration is important, we are here to help you. Watch this video to learn more.
PM-GB-CBR-WCNT-230006 | December 2023
To support you when deciding if a patient might be suitable for Vocabria and Rekambys.
PM-GB-CBR-WCNT-240006 | February 2024
Key data
Key data from CARISEL: A European, open-label phase III implementation effectiveness study evaluating every-2-month VOCABRIA + REKAMBYS in real-world settings.
PM-GB-CBR-WCNT-230008 | December 2023
Key data from SOLAR: The first head-to-head study comparing every-2-month VOCABRIA + REKAMBYS vs daily oral therapy with BIC/FTC/TAF.
PM-GB-CBR-WCNT-230009 | December 2023
BIC/FTC/TAF=bictegravir/emtricitabine/tenofovir alafenamide; BMI=body mass index; FAQ=frequently asked question; HCP=healthcare professional; ID=identification; PLHIV=people living with HIV
REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.
PM-GB-CBR-WCNT-230004 | July 2024
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.